Saturday 17 October 2026 Export OVID’s income statement to Excel — free account

Ovid Therapeutics

Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024. In the quarter to June 2026, revenue grew 463.9%, EPS fell 33.3%, free cash flow fell 268.5% and total debt fell 11.7%, each against the same quarter a year earlier.

2.15 0.11 −4.87%

Follow OVID

Alert me

Market cap: $441.4M
P/E: 0.0×
Fwd P/E: −5.0×
Dividend yield: —
F-score: 4/9
Altman Z: 0.22
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	2	—	—	—	—	—	—	—	—

Insider Ownership 8.39%

Capital & Financial Ratios $m

Market Cap 441.37

Revenue 7.86

Net Income (34.49)

Free Cash Flow (54.77)

Net Debt (105.99)

Current Ratio 12.39

Debt/Equity 0.05

P/E ratio 0.00

Fwd P/E (4.97)

P/S ratio 54.05

P/B ratio 2.02

Past 5Y EPS Growth —

This Y EPS Growth (56.74%)

Next Y EPS Growth (6.96%)

Next Y revenue growth (89.08%)

Next 5Y EPS Growth (20.07%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 49.69%

10-year low 10-year high

P/B against its own 10 years 55.22%

10-year low 10-year high

EV/Sales against its own 10 years 54.28%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	106	53	70	117
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	4	3	5	6
	110	56	74	124

	2023	2024	2025	Q'26
Payables	4	3	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	11	11	8	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	(10.48%)	68.99%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	6.74%	24.53%	(0.41%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	1	—	—	—
’25	0	6	0	1	7
’24	0	0	0	0	1
’23	0	0	0	0	0
’22	1	—	0	0	2
’21	208	—	—	—	208

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	(18)	—	—	—
’25	(10)	(5)	(13)	(10)	(38)
’24	(17)	(14)	(15)	(10)	(56)
’23	(12)	(12)	(10)	(12)	(46)
’22	(20)	(13)	(13)	(9)	(55)
’21	161	(19)	(11)	(12)	119
’20	(18)	(17)	(1)	(15)	(52)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	(18)	—	—	—
’25	(10)	(5)	(13)	(10)	(38)
’24	(17)	(14)	(15)	(10)	(56)
’23	(12)	(12)	(10)	(12)	(46)
’22	(20)	(15)	(13)	(9)	(57)
’21	161	(19)	(11)	(12)	118
’20	(19)	(17)	(2)	(15)	(52)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.12)	(0.08)	—	—	—
’25	(0.14)	(0.06)	(0.17)	0.14	(0.23)
’24	(0.17)	0.12	(0.20)	(0.13)	(0.37)
’23	(0.19)	(0.18)	(0.16)	(0.22)	(0.74)
’22	(0.23)	(0.21)	(0.17)	(0.16)	(0.77)
’21	2.53	(0.23)	(0.17)	(0.38)	1.76
’20	(0.37)	(0.41)	(0.28)	(0.34)	(1.39)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	5.28	2.42	1.53	1.80	2.27	1.41	1.80	0.68	0.24	Analyst estimates 2026–2028 Powerpack
	High	—	15.93	11.45	5.24	9.40	4.80	3.55	4.14	4.10	2.01
People
People	Employees	31	43	55	59	67	57	44	40	23	23
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.19	3.66	0.03	0.01	0.02	0.32
Income, $m
Income, $m	Revenue	—	—	—	—	13	208	2	0	1	7
	Gross margin, %	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(22)	(65)	(52)	(60)	(81)	124	(54)	(52)	(26)	(17)
	EBT margin, %	0.00	0.00	0.00	0.00	(642.26)	59.58	(3,604.78)	(13,351.79)	(4,670.14)	(240.13)
	Net income	(22)	(65)	(52)	(60)	(81)	123	(54)	(52)	(26)	(17)
	Depreciation	0	0	0	0	0	0	1	1	1	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.22	3.09	0.02	0.01	0.01	0.10
	Earnings	(2.28)	(3.35)	(2.11)	(1.54)	(1.39)	1.78	(0.77)	(0.74)	(0.37)	(0.23)
	Cash flow	(1.81)	(1.63)	(1.85)	(1.30)	(0.88)	1.76	(0.78)	(0.65)	(0.79)	(0.52)
	Capex	(0.02)	0.00	(0.01)	(0.01)	(0.01)	0.00	(0.02)	0.00	0.00	0.00
	Free cash flow	(1.83)	(1.63)	(1.86)	(1.31)	(0.89)	1.75	(0.80)	(0.65)	(0.79)	(0.52)
	Book value	5.01	4.31	1.58	1.79	0.75	2.66	1.88	1.24	0.96	1.77
	Shares, m	10	19	25	39	58	67	70	71	71	74
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	1.81	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	0.00	0.65	597.77	116.51	16.57
	P/B	—	—	—	—	3.09	1.21	1.03	2.67	0.97	0.92
	EV/Sales	—	—	—	—	0.00	0.00	0.11	365.43	46.44	8.62
	EV/FCF	—	—	—	—	(1.21)	0.24	(0.42)	(3.12)	(0.47)	(1.63)
Cash, $m
Cash, $m	Operating cash flow	(18)	(31)	(46)	(51)	(52)	119	(55)	(46)	(56)	(38)
	Capex	0	0	0	0	0	0	(1)	0	0	—
	Free cash flow	(18)	(32)	(46)	(51)	(52)	118	(57)	(46)	(56)	(38)
Balance, $m
Balance, $m	Working capital	49	83	35	69	53	176	124	98	45	66
	Total debt	—	—	—	0	0	—	16	15	13	12
	Net debt	(52)	(87)	(42)	(76)	(72)	(188)	(113)	(91)	(40)	(58)
	Shareholders’ equity	49	83	39	70	44	180	132	88	68	131
Returns, %
Returns, %	ROA	(36.33)	(90.97)	(75.82)	(94.11)	(103.38)	88.61	(30.97)	(34.98)	(22.38)	(14.33)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(180.14)	0.00	(135.38)	(36.33)
	ROE	(38.20)	(97.66)	(85.04)	(111.11)	(142.60)	107.30	(34.72)	(47.57)	(33.88)	(17.51)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AUTL Autolus Therapeutics PLC Sponsored ADR	$457.8M	— (loss-making)	— (loss-making)	+118.37% (above 0%: growing)	n/m	+67.55% (above 0%: growing)	55.20%	(95.95%)	Compare
OCS Oculis Holding AG	$456.8M	— (loss-making)	— (loss-making)	+23.96% (above 0%: growing)	n/m	−10.40% (below 0%: shrinking)	100.00%	(7,603.42%)	Compare
EPRX Eupraxia Pharmaceuticals Inc.	$446.2M	— (loss-making)	—	—	n/m	−56.41% (below 0%: shrinking)	—	0.00%	Compare
MPLT MapLight Therapeutics, Inc.	$445.7M	— (loss-making)	—	—	n/m	−31.91% (below 0%: shrinking)	—	0.00%	Compare
OVID Ovid Therapeutics	$441.4M	— (loss-making)	— (loss-making)	+463.85% (above 0%: growing)	n/m	−268.54% (below 0%: shrinking)	100.00%	(2,141.61%)
PROK ProKidney Corp.	$439.9M	— (loss-making)	— (loss-making)	−32.13% (below 0%: shrinking)	n/m	−28.03% (below 0%: shrinking)	100.00%	(32,248.67%)	Compare
INDP Indaptus Therapeutics, Inc.	$437.7M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
PRTA Prothena Corporation plc	$436.4M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$433.6M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$442.8M	—	—	−4.08%	—	−8.57%	77.60%	(47.97%)

All 614 Biotechnology stocks →

Ovid Therapeutics (OVID) key facts

Strength: Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024.
Ovid Therapeutics (OVID) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OVID traded at $2.15, a market capitalization of $441.4 million.
Return on equity was −17.5% and debt-to-equity 0.05.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.22 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.